Information Provided By: 
Fly News Breaks for October 1, 2015
ESRX, REGN
Oct 1, 2015 | 05:54 EDT
Piper Jaffray analyst Edward Tenthoff says Express Scripts (ESRX) hinted that the anti-PCSK9 launches including Regeneron's (REGN) Praluent were off to a slow start. The company stated that the drugs were not on track to be "budget busters," Tenthoff tells investors in a research note. The analyst still expects a slow launch for Praluent due to the lack of cardiovascular outcomes data and strict reimbursement. He reiterates a Neutral rating on Regeneron with a $607 price target.
News For REGN;ESRX From the Last 2 Days
There are no results for your query REGN;ESRX
